Aclaris Therapeutics, Inc.ACRSNASDAQ
LOADING
|||
Switch Symbol:
EPS Growth Accelerating
Trending higher, above historical average, slight contraction.
Left:
||||
Year-over-year earnings per share growth rate
Latest
7.69%
↑ 117% above average
Average (39q)
-44.79%
Historical baseline
Range
High:94.88%
Low:-1042.86%
CAGR
-4.8%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 7.69% |
| Q2 2025 | -8.33% |
| Q1 2025 | 88.12% |
| Q4 2024 | -818.18% |
| Q3 2024 | 26.67% |
| Q2 2024 | 37.50% |
| Q1 2024 | -1042.86% |
| Q4 2023 | 94.88% |
| Q3 2023 | 2.38% |
| Q2 2023 | -7.69% |
| Q1 2023 | 22.00% |
| Q4 2022 | -56.25% |
| Q3 2022 | -28.00% |
| Q2 2022 | 10.71% |
| Q1 2022 | 24.32% |
| Q4 2021 | -5.71% |
| Q3 2021 | -2.94% |
| Q2 2021 | 40.35% |
| Q1 2021 | -90.00% |
| Q4 2020 | -20.00% |
| Q3 2020 | 10.71% |
| Q2 2020 | 24.32% |
| Q1 2020 | 17.78% |
| Q4 2019 | 66.42% |
| Q3 2019 | -10.74% |
| Q2 2019 | -32.97% |
| Q1 2019 | 8.08% |
| Q4 2018 | 6.60% |
| Q3 2018 | -4.95% |
| Q2 2018 | -3.06% |
| Q1 2018 | -32.43% |
| Q4 2017 | -17.46% |
| Q3 2017 | -12.50% |
| Q2 2017 | -16.67% |
| Q1 2017 | 2.04% |
| Q4 2016 | 2.00% |
| Q3 2016 | 19.35% |
| Q2 2016 | 4.62% |
| Q1 2016 | -150.00% |
| Q4 2015 | 52.73% |